
Dexcom reported higher third-quarter revenue and adjusted earnings, while raising its full-year sales outlook to $5.20 billion to $5.25 billion.
Dexcom reported third-quarter revenue of $1.34 billion, up 11% year over year, and announced a new $1 billion share repurchase program. Adjusted earnings per share were $0.73, above market expectations, according to finanzen.net.
Adjusted operating income reached $339.5 million, equal to a 25.3% margin. The company updated its full-year revenue forecast to $5.20 billion to $5.25 billion.
Dexcom said new patient starts reached a record in the quarter, with the largest increase among people with Type 2 diabetes who do not use insulin. As of 20:00 UTC Friday, shares traded at $82.29, up 2.95% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.